Stock Movers Ryanair Up, Diageo's Tariff Losses, Roche Up
May 19, 2025
Ryanair reports strong summer demand, indicating travelers are sticking closer to home with rising fares. Meanwhile, Diageo navigates challenges from U.S. tariffs while expecting better sales in the latter half of the year. In a groundbreaking development, U.S. regulators approve a blood test for Alzheimer's, potentially transforming patient diagnosis and treatment. This news has significant implications for drug companies like Roche and BioArctic, as the industry prepares for upcoming earnings reports.
AI Snips
Chapters
Transcript
Episode notes
Ryanair's Strong Summer Demand
- Ryanair sees strong summer travel demand within Europe despite uncertainty about US routes.
- This boosts Ryanair stock and lifts shares of other European airlines like EasyJet and Lufthansa.
Diageo Faces US Tariff Challenges
- Diageo experiences mixed US consumer behavior amid tariffs, with some stockpiling products before tariff hikes.
- The company's shares are down significantly over the past year, showing market concern about tariff impact.
Alzheimer's Diagnosis Breakthrough
- US regulators approved the first blood test to diagnose Alzheimer’s, detecting amyloid protein early.
- This breakthrough potentially increases diagnoses and benefits drug companies like Roche and BioArctic.